3期KEYNOTE-006研究的中期分析显示,在晚期黑色素瘤患者中,总体和无进展生存期派姆单抗优于伊匹单抗。我们介绍最终的协议指定的生存分析。 Methods方法 In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countrie...
We present outcomes from the 5-year follow-up of this studythe longest to date in a randomized phase 3 trial of pembro in advanced cancer. Long-term follow-up for pts completing 2 years of pembro and data for pts treated with a second course (2nd course) of pembro are also reported....